Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Heavily Pretreated Patients With Hematological Malignancies. Hematol Meeting Rep 2009, 1 (8). https://doi.org/10.4081/hmr.v1i8.297.